Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI

Table 2

Baseline characteristics.

	Interruption of DAPT within 12 months after PCI		value
	No (n = 2809)	Yes (n = 1122)
Age, years	59.05 ± 10.00	59.33 ± 10.48	0.445
Male	2155 (76.7)	854 (76.1)	0.687
Hyperlipidemia	1954 (69.6)	751 (66.9)	0.108
Hypertension	1926 (68.6)	764 (68.1)	0.773
Diabetes mellitus	1309 (46.6)	545 (48.6)	0.263
Chronic kidney disease	248 (8.8)	104 (9.3)	0.662
Current smoker	1601 (57.0)	627 (55.9)	0.525
Heart failure	69 (2.5)	22 (2.0)	0.351
Peripheral artery disease	89 (3.2)	38 (3.4)	0.727
History of myocardial infarction	607 (21.6)	240 (21.4)	0.880
Prior PCI	630 (22.4)	256 (22.8)	0.792
Prior CABG	139 (4.9)	53 (4.7)	0.768
History of stroke	331 (11.8)	152 (13.5)	0.128
History of major bleeding	17 (0.6)	12 (1.1)	0.124
Body mass index, kg/m^2	26.10 ± 3.14	25.97 ± 3.28	0.279
LVEF, %	62.42 ± 7.63	62.42 ± 7.46	0.991
Clinical presentation			0.010
Stable coronary artery disease	1241 (44.2)	445 (39.7)
Acute coronary syndrome	1568 (55.8)	677 (60.3)
UA/NSTEMI	1234 (43.9)	527 (46.9)	0.084
STEMI	334 (11.9)	150 (13.4)	0.203
White blood cell count, 10^9/L	6.80 ± 1.64	6.84 ± 1.63	0.482
Hemoglobin, g/dL	14.25 ± 1.58	14.18 ± 1.56	0.220
Platelet count, 10^9/L	204.08 ± 53.91	205.22 ± 53.21	0.550
ARC-HBR	573 (20.4)	264 (23.5)	0.032
Discharge medication
Aspirin	2778 (98.9)	1112 (99.1)	0.554
Clopidogrel	2766 (98.5)	1110 (98.9)	0.266
Ticagrelor	9 (0.3)	8 (0.7)	0.107
β-blocker	2584 (92.0)	1033 (92.1)	0.935
ACEI/ARB	1731 (61.6)	694 (61.9)	0.893
CCB	1408 (50.1)	550 (49.0)	0.531
Statin	2701 (96.2)	1068 (95.2)	0.168

Values are mean ± SD for continuous variables and n (%) for categorical variables. ACS indicates acute coronary syndrome; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor antagonists; ARC-HBR, Academic Research Consortium-High Bleeding Risk; CCB, calcium channel blockers; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; and UA, unstable angina. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m² of body surface area. Spontaneous (nonintracranial) bleeding requiring hospitalization or transfusion.